6 research outputs found

    An analysis of the cost-volume relationships within the aircraft program of the Naval Air Rework Facility, Alameda, California

    Get PDF
    The purpose of this research project is to examine the cost behavior of the Naval Air Rework Facility, Alameda, California, aircraft program in relation to variations in aircraft rework workloads, and to develop cost-volume relationships useable in support of pricing and workload decisions. Analysis of four years of quarterly direct and indirect cost data provided the base from which total cost-volume models were derived for the four aircraft program segments (A-6, P-3, S-3, and A-3). The results of this study indicate that significant cost-volume relationships exist not only with the direct costs but also with many associated indirect aircraft program costs. The study further suggests that other factors, such as rate and direction of volume changes and levels of personnel strengths, may have predictable affects on aircraft reworks costs.http://archive.org/details/analysisofcostvo00ferrCommander, United States NavyApproved for public release; distribution is unlimited

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Role of Hormones in Pilosebaceous Unit Development

    Full text link
    corecore